Approved regulations allow for some flexibility for drugs that can be redistributed or qualify for manufacturer credit.
Erdafitinib is first targeted therapy for FGFR3 or FGFR2 genetic alteration.
Key updates from the Seattle, WA, conference in March.
Health systems employ Artifical Intelligence and integrated medication management to address diversion.
Results from DrugTopics' annual salary survey suggested that salaries, raises, and bonuses fail to improve pharmacists' professional satisfaction.